TAIRX, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.95 TWD | -0.64% |
|
-1.77% | +44.26% |
| Apr. 11 | TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 6.92M 213K | Sales 2023 | 5.08M 156K | Capitalization | 2.44B 74.77M |
|---|---|---|---|---|---|
| Net income 2022 | -212M -6.51M | Net income 2023 | -212M -6.51M | EV / Sales 2022 | 438 x |
| Net cash position 2022 | 343M 10.53M | Net cash position 2023 | 648M 19.89M | EV / Sales 2023 | 352 x |
| P/E ratio 2022 |
-15.8
x | P/E ratio 2023 |
-11.7
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 52.99% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.64% | ||
| 1 week | -1.77% | ||
| Current month | +14.73% | ||
| 1 month | +55.80% | ||
| 3 months | +62.29% | ||
| 6 months | +50.10% | ||
| Current year | +44.26% |
1 week
36.65
39.95
1 month
24.8042.45
Current year
23.2042.45
1 year
23.2042.45
3 years
23.2089.50
5 years
12.8689.50
10 years
12.8689.50
| Managers | Title | Age | Since |
|---|---|---|---|
Yi Wen Chu
FOU | Founder | - | 11-08-21 |
Du Shieng Chien
CEO | Chief Executive Officer | - | 11-08-21 |
Jackson Huang
DFI | Director of Finance/CFO | - | 15-10-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Du Shieng Chien
CEO | Chief Executive Officer | - | 11-08-21 |
Yi Wen Chu
FOU | Founder | - | 11-08-21 |
Hsiu Hui Li
BRD | Director/Board Member | - | 11-08-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 38.95 | -0.64% | 201,708 |
| 24-04-23 | 39.2 | +0.51% | 291,075 |
| 24-04-22 | 39 | +3.04% | 436,540 |
| 24-04-19 | 37.85 | -3.81% | 924,662 |
| 24-04-18 | 39.35 | -0.76% | 198,716 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.
| 1st Jan change | Capi. | |
|---|---|---|
| +44.26% | 131M | |
| +4.09% | 43.84B | |
| +46.79% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- 6580 Stock
